The global nausea medicine market is set to expand at CAGR of 7.2% during the forecast period (2016-2023), reports Market Research Future (MRFR). Nausea is a kind of stomach distress with involuntary urge to vomit due to a number of factors, such as stomach upset or gastric ulcers. Nausea is common among children and pregnant women. Few common indications of nausea are motion sickness, seasickness, medication, and chemotherapy.
Get a FREE Sample Report with Complete TOC @ https://www.marketresearchfuture.com/sample_request/757
There has been an increase in gastrointestinal diseases such as gastroesophageal reflux disease (GERD), and viral gastroenteritis, which are mainly responsible for nausea. This increase is bound to propel the market growth in coming years as well. Moreover, availability of a wide range of treatment for nausea is envisaged to fuel the market growth. Apart from this, changing lifestyle with shift in dietary habits has brought about a positive influence on the market size.
Although the market is treading on a positive growth path, it will encounter some restraining factors. These are namely high preference for home remedies, particularly in emerging regions. Ingredients like ginger, lemon, garlic and such food items give tough competition to the conventional form of treatment.
However, it is also observed that these home remedies are temporary solutions, without healing completely. Thus, the market for nausea medicine will remain unaffected, as stated by industry experts.
The global nausea medicine market is segmented into type, mode of administration, indication and end user.
By type, the market is segmented on the basis of antacids, antagonists, anti-anxiety drugs, steroids, cannabinoids and others. Antacids are sub-segmented into serotonin (5-HT3) antagonists, NK-1 antagonists and dopamine antagonists.
Based on mode of administration, the market is segmented into intravenous therapy (IVs), tablets and others. The tablets segment is surging at a swift growth rate as nausea tablets are easier to take and are more convenient to consume.
By indication, the market is segmented into gastroesophageal reflux disease (GERD), viral gastroenteritis, motion sickness and seasickness, medication, chemotherapy, and others. With increasing number of patients experiencing nausea associated with chemotherapeutic drug use, the segment of chemotherapy-induced nausea is growing at an exceptional rate. Based on end user, the market is segmented into hospitals, clinics, pharmaceutical companies and others.
The Americas claims the largest market for nausea medicine on account of rising prevalence of gastrointestinal diseases such as GERD. Also, the prevalence of nausea is increasing among school-going children, further pushing the market growth upward. Prevalence of viral gastroenteritis is growing in the United States (U.S), particularly among the pediatric population. Furthermore, the prevalence of acute gastrointestinal diseases is found to be high in Canada, which has been instrumental in the market expansion in the region as well.
Europe has secured the second largest market for nausea medicine due to the high prevalence of nausea and vomiting among pregnant women, the population of which is increasing consistently in the region. In addition, there is a massive demand for the diagnosis and treatment of nausea, especially among pregnant women which will fuel the market growth in Europe. There is also prevalence of chemotherapy-induced nausea in the region which is increasing steadily. This factor will play a stellar role in increasing the demand for nausea medicine in the region in the foreseeable future.
The APAC market is projected to grow at the fastest rate on the back of changing lifestyle and growing geriatric population. Also, increasing cases of viral gastritis and gastric ulcer in the region has spurred the demand for nausea medicines in the region.
Lastly, the Middle East & Africa have exhibited a steady rise in the market, which can be attributed to rising prevalence of chemotherapy-induced nausea.
Pfizer (U.S.), GlaxoSmithKline (U.S.), ANI Pharmaceuticals, Inc. (U.S.), Merck & Co., Inc. (U.S.), Sanofi (France), TESARO, Inc. (U.S.), and F. Hoffmann-La Roche Ltd (Switzerland) are some of the key players contributing to the global nausea medicine market.
- August 2018 – The Korean Ministry of Food and Drug Safety has approved the nausea therapy Akynzeo for chemotherapy patients. This therapy is a joint venture by Helsinn Healthcare and CJ Healthcare, with indications of acute and delayed nausea for patients who are undergoing highly emetogenic cancer chemotherapy along with moderately emetogenic cancer chemotherapy.
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
+1 646 845 9312